HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EC Science Committee Gives Qualified OK For 4-MBC In Sunscreens

This article was originally published in The Tan Sheet

Executive Summary

The European Commission's Scientific Committee on Consumer Products responds to data from the personal care product industry and decides that, at least temporarily, 4-methylbenzylidene camphor is safe in sunscreens at concentrations up to 4 percent

You may also be interested in...



FDA Clarifies Skin Protectant Labeling, Ingredient Combination Options

FDA attempts to clarify the active ingredients manufacturers may combine in OTC skin protectant drug products and details corresponding label requirements in draft guidance released Aug. 1

US FDA Again Finds Talc-Containing Cosmetics Asbestos-Free In 2022 Testing

No asbestos was detected in product samples from brands including Lancome Paris, Clinique, Gucci, Avon, and Neutrogena, the FDA says. Like in 2021, the agency’s 2022 testing provides assurances after 17% of talc-containing cosmetic products analyzed in 2019 were found to be tainted with asbestos.

Beauty Without Microplastic: Consumer Expectations For Cosmetic Products May Have To Change

Kelly Dobos, a consultant, adjunct professor, and former president of the Society of Cosmetic Chemists, discusses the challenges facing beauty businesses and formulators, and the changes to cosmetic products that could be coming consumers’ way, under developing bans on microplastic use.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS137801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel